NEW YORK (360Dx) – The US Food and Drug Administration recently launched an innovation challenge through which it hopes to advance the development of promising technologies for in vitro diagnostics that help combat the opioid crisis.

As part of the innovation challenge, the agency will work closely with selected candidates to help them achieve accelerated approvals to market their technologies, the agency said. Ultimately, its objective is to identify technologies and solutions that target pain, addiction, and diversion.